Clinical trial · Observational
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
| Heart Failure | — | UNRESOLVED | — |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Accelerometer physical activity monitoring | Other | — | UNRESOLVED |
| Cardiac magnetic resonance imaging (MRI) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All Study Participants
- description
- This is an observational study where all study participants are within a single group. Participants will have testing performed at baseline and again at follow-up \>= 3 years after the initial assessment.
- interventionNames
- Diagnostic Test: Cardiac magnetic resonance imaging (MRI)
- Other: Accelerometer physical activity monitoring
Primary outcomes (1)
- measure
- Left ventricular ejection fraction (LVEF)
- timeFrame
- 3 - 5 years
- description
- LVEF is an assessment of left ventricular global systolic function.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 13 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: * English and Spanish speaking male and female subjects, ages 13-39 years old * Diagnosis of cancer at age \<22 years * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior. Exclusion Criteria: * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants. * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia. * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus). * Pregnancy (at the time of enrollment).
References
Publications (1)
- DERIVEDNarayan HK, Chen S, Wong FL, Young N, Qi A, Davis C, Hegde S, Gloude N, Leger KJ, Getz KD, Contijoch F, Ness K, Ky B, Kuo D, Hartman SJ, Armenian SH. The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross-Sectional Study. Pediatr Blood Cancer. 2026 Jul 25:e70523. doi: 10.1002/1545-5017.70523. Online ahead of print. PMID 42499264